HDAX Therapeutics

Healthcare & Life Sciences

Recent Finacing

Recent Raise

HDAX Therapeutics is developing next-generation HDAC6 inhibitors to treat neurological and cardiometabolic diseases.

Total Funding

Headquarters

Founded

Website

Focus Areas

preclinical development

pipeline advancement

HDAC6 inhibitors

neurological diseases

cardiometabolic diseases

Investors